 Everglyptin registered trademark symbol EVO, a novel depeptidyl peptidase IV, DPP IV, inhibitor was found to be effective at treating diabetic cardiomyopathy, DCM. It reduced blood sugar levels, improved insulin sensitivity, and protected against cardiac lipotoxicity and mitochondrial damage. This suggests that EVO may be a promising therapeutic option for DCM. This article was authored by Tronkovam, Dahuaitininian, DuMie, and others.